RBM25/LUC7L3 Function in Cardiac Sodium Channel Splicing Regulation of Human Heart Failure

Trends in Cardiovascular Medicine

Volumn 23, Issue 1, 2013, Pages 5-

  Gao, Ge ^a   Dudley, Samuel C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SODIUM CHANNEL NAV1.5; VOLTAGE GATED SODIUM CHANNEL; RED120 PROTEIN, HUMAN; RNA BINDING PROTEIN; SCN5A PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; CARDIOVASCULAR RISK; EXON; GENE EXPRESSION; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HUMAN; HUMAN GENOME; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; UPREGULATION; ARTICLE; GENETICS; METABOLISM;

ALTERNATIVE SPLICING; HEART FAILURE; HUMANS; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; RNA, MESSENGER; RNA-BINDING PROTEINS;

MLCS; MLOWN;

EID: 84872130937     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.08.003     Document Type: Review

References (37)

1. Abriel H., Kass R.S. Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. Trends Cardiovasc Med 2005, 15:35-40.
2. Akhtar M., Breithardt G., Camm A.J., et al. CAST and beyond: Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 1990, 81:1123-1127.
3. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
4. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140-2150.
5. Carrithers M.D., Dib-Hajj S., Carrithers L.M., et al. Expression of the voltage-gated sodium channel NaV1. 5 in the macrophage late endosome regulates endosomal acidification. J Immunol 2007, 178:7822-7832.
6. Chung S.K., MacCormick J.M., McCulley C.H., et al. Long QT and Brugada syndrome gene mutations in New Zealand. Heart Rhythm 2007, 4:1306-1314.
7. Claus E.B., Park P.J., Carroll R., et al. Specific genes expressed in association with progesterone receptors in meningioma. Cancer Res 2008, 68:314-322.
8. Dorian P., Al-Khalidi H.R., Hohnloser S.H., et al. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol 2008, 52:1076-1083.
9. Du H., Cline M.S., Osborne R.J., et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol 2010, 17:187-193.
10. + channel activity. FEBS Lett 2004, 569:191-194.
11. Gao G., Dudley S.C. Redox regulation, NF-κB, and atrial fibrillation. Antioxid Redox Signal 2009, 11:2265-2277.
12. Gao G., Xie A., Huang S.C., et al. Role of RBM25/LUC7L3 in abnormal cardiac sodium channel splicing regulation in human heart failure. Circulation 2011, 124:1124-1131.
13. Gellens M.E., George A.L., Chen L.Q., et al. Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci U S A 1992, 89:554-558.
14. + channel α-subunit gene (SCN5A) to band 3p21. Cytogenet Cell Genet 1995, 68:67-70.
15. Hong K., Guerchicoff A., Pollevick G.D., et al. Cryptic 5' splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol 2005, 38:555-560.
16. Inuzuka Y., Okuda J., Kawashima T., et al. Suppression of phosphoinositide 3-kinase prevents cardiac aging in mice. Circulation 2009, 120:1695-1703.
17. Jurica M.S., Moore M.J. Pre-mRNA splicing: Awash in a sea of proteins. Mol Cell 2003, 12:5-14.
18. Kamath G.S., Mittal S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Prog Cardiovasc Dis 2008, 50:439-448.
19. Maniatis T., Tasic B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 2002, 418:236-243.
20. Matlin A.J., Clark F., Smith C.W. Understanding alternative splicing: Towards a cellular code. Nat Rev Mol Cell Biol 2005, 6:386-398.
21. Modrek B., Resch A., Grasso C., Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 2001, 29:2850-2859.
22. Morganroth J., Nestico P.F., Horowitz L.N. A review of the uses and limitations of tocainide-A class IB antiarrhythmic agent. Am Heart J 1985, 110:856-863.
23. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
24. Nishii Y., Morishima M., Kakehi Y., et al. CROP/Luc7A, a novel serine/arginine-rich nuclear protein, isolated from cisplatin-resistant cell line. FEBS Lett 2000, 465:153-156.
25. Novak A.J., Slager S.L., Fredericksen Z.S., et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009, 69:4217-4224.
26. Otagiri T., Kijima K., Osawa M., et al. Cardiac ion channel gene mutations in sudden infant death syndrome. Pediatr Res 2008, 64:482-487.
27. Pan Q., Shai O., Lee L.J., et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008, 40:1413-1415.
28. Ricco R., Kanduc D. Hepatitis B virus and Homo sapiens proteome-wide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins. Biologics 2010, 4:75-81.
29. Roselli F., Livrea P., Jirillo E. Voltage-gated sodium channel blockers as immunomodulators. Recent Pat CNS Drug Discov 2006, 1:83-91.
30. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer 2010, 10:389-402.
31. Shang L.L., Pfahnl A.E., Sanyal S., et al. Human heart failure is associated with abnormal C-terminal splicing variants in the cardiac sodium channel. Circ Res 2007, 101:1146-1154.
32. Shang L.L., Sanyal S., Pfahnl A.E., et al. NF-κB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol 2008, 294:C372-C379.
33. Shibata E.F., Brown T.L., Washburn Z.W., et al. Autonomic regulation of voltage-gated cardiac ion channels. J Cardiovasc Electrophysiol 2006, 17:S34-S42.
34. Singh S., Murawski M.M. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs. J Cardiovasc Pharmacol Ther 2007, 12:175-180.
35. Stearman R.S., Dwyer-Nield L., Zerbe L., et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005, 167:1763-1775.
36. Ye B., Valdivia C.R., Ackerman M.J., Makielski J.C. A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation. Physiol. Genomics 2003, 12:187-193.
37. Zhou A., Ou A.C., Cho A., et al. Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5' splice site selection. Mol Cell Biol 2008, 28:5924-5936.